Skip to main content
Kuros Biosciences Ltd. logo

Kuros Biosciences Ltd. — Investor Relations & Filings

Ticker · KURN ISIN · CH0325814116 LEI · 5299006U5POB2AVTT709 SW Manufacturing
Open in API
Filings indexed 207 across all filing types
Latest filing 2015-07-29 Earnings Release
Country CH Switzerland
Listing SW KURN

About Kuros Biosciences Ltd.

https://kurosbio.com/

Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.

Recent filings

Filing Released Lang Actions
Cytos Biotechnology Ltd Reports the Financial Results of the First Half Year 2015
Earnings Release Classification · 100% confidence The document explicitly states it reports the "Financial Results of the First Half Year 2015". It provides detailed financial figures, including revenue, costs, net income/loss, and balance sheet items for the six-month period ended June 30, 2015. This content aligns perfectly with the definition of a comprehensive financial report for a period shorter than a year, which corresponds to the Interim / Quarterly Report (IR) category. Although it is presented as an 'Ad-hoc' announcement, the core content is the detailed half-year report summary, not just a brief announcement of its publication (which would be RPA or RNS). H1 2015
2015-07-29 English
Annual Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders approve all resolutions
AGM Information Classification · 99% confidence The document explicitly mentions 'Annual Shareholders’ Meeting' multiple times in the title and body. It reports that shareholders approved all resolutions at this meeting. The filing is categorized as 'Ad-hoc' and relates directly to the proceedings of the Annual General Meeting (AGM). This aligns perfectly with the definition for AGM Information (AGM-R). The document length is short (3319 chars), but its content is the summary/result of the meeting itself, not just an announcement that materials are available, making AGM-R more specific than RPA or RNS.
2015-06-29 English
Cytos Biotechnology AG invites to the Annual General Meeting
Report Publication Announcement Classification · 99% confidence The document explicitly states, "Cytos Biotechnology AG invites to the Annual General Meeting" and later, "Cytos Biotechnology Ltd (“Cytos”) today announced that the Annual General Meeting 2015 will take place...". The key phrase is 'Annual General Meeting' (AGM). This directly corresponds to the AGM Information category (AGM-R). Although it is an announcement, the content is specifically about the meeting itself, rather than just announcing the publication of a separate report (which would be RPA or RNS). Therefore, AGM-R is the most precise classification.
2015-06-08 English
Cytos Biotechnology AG: bond conversion into equity effective
Share Issue/Capital Change Classification · 99% confidence The document is explicitly labeled as an "Ad-hoc" announcement released on May 8, 2015, concerning the completion of a convertible bond conversion into equity, resulting in the issuance of new shares and the elimination of debt. This type of material event disclosure, which is not a full periodic report (like 10-K or IR) or a standard earnings release (ER), fits best under the general category for regulatory announcements that don't fit elsewhere, which is 'Regulatory Filings' (RNS). While it relates to capital structure changes (CAP), the primary function here is the immediate public disclosure of a material event as required by listing rules, making RNS the most appropriate general classification for an ad-hoc filing.
2015-05-08 English
Cytos Biotechnology AG will become debt-free
Capital/Financing Update Classification · 98% confidence The document is explicitly labeled as an "Ad-hoc" announcement released on May 4, 2015. The content details a significant financial restructuring event: the conversion of all bonds into equity and a settlement with loan note holders, resulting in the company becoming debt-free. This type of immediate, material financial update that is not a full periodic report (like 10-K or IR) or a standard earnings release (ER) falls best under 'Capital/Financing Update' (CAP) as it directly concerns the capital structure and debt elimination. It is too specific for the general 'RNS' fallback, and it is not a presentation (IP), a management discussion (MDA), or a dividend notice (DIV).
2015-05-04 English
Cytos Biotechnology Ltd Reports the Financial Results of 2014
Earnings Release Classification · 100% confidence The document is titled 'Cytos Biotechnology Ltd Reports the Financial Results of 2014' and presents 'Full year consolidated financial figures 2014' including Balance Sheet data, Revenues, Net Loss, and Cash Burn comparisons between FY 2014 and FY 2013. This content strongly indicates a comprehensive annual financial disclosure. Although it is presented as an 'Ad-hoc' announcement via EQS, the core content is the full-year financial results summary. The document explicitly states, 'The detailed Annual Report 2014 can be downloaded at: [link]'. According to Rule 2 (The 'MENU VS MEAL' Rule), if the document is short and announces the availability of a full report, it should be classified as RPA or RNS. However, this document (7954 chars) contains substantial financial tables and narrative analysis of the full year's performance, making it more than just a simple announcement wrapper. It functions as a summary/release of the annual results. Given the comprehensive nature of the financial data presented for the full year, it aligns best with the Annual Report (10-K) category, even if it's a summary version released via an ad-hoc mechanism, as it covers the entire fiscal year's performance. If a dedicated 10-K filing is not present, this comprehensive annual summary is the closest fit. The document title and content focus on 'Financial Results of 2014'. FY 2014
2015-04-28 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.